This book investigates the ethical implications of how the promise of unproven or experimental medical interventions is leveraged to exploit vulnerable patients. Jeremy Snyder, a professor of health sciences, examines the intersection of hope, commercial interest, and regulatory oversight. He argues that while hope is a necessary component of the patient experience, it is frequently weaponized by stakeholders to bypass safety standards and extract financial gain from those facing terminal or chronic conditions.

Experts in bioethics frequently cite this work as a critical examination of the tension between patient autonomy and corporate accountability. Readers note the clinical precision with which Snyder dissects the systemic vulnerabilities inherent in modern healthcare markets.